Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Recombinetics
Main focus: Development of gene-edited animals for various applications
Diseases (gene editing): Organ failure
Genome editing tool: CRISPR, TALEN
Funding stage: Private
Location: Minneapolis, Minnesota, USA
Website: https://recombinetics.com/
Recombinetics is gene-editing company, mainly focused on genetically engineering animals for agricultural and biomedical applications. The company's biomedical operations mainly take place through its subsidiaries, Regenevida, Surrogen and Makana Therapeutics. Regenevida develops patient-derived organ cells for improved transplantation, while Surrogen has been established to genetically engineer pigs to create improved disease models. Makana Therapeutics aims to genetically engineer pigs with the aim to enable xenotransplantation, thereby accommondating the increasing demand for transplantable organs.